1
|
Taasti VT, Decabooter E, Eekers D, Compter I, Rinaldi I, Bogowicz M, van der Maas T, Kneepkens E, Schiffelers J, Stultiens C, Hendrix N, Pijls M, Emmah R, Fonseca GP, Unipan M, van Elmpt W. Clinical benefit of range uncertainty reduction in proton treatment planning based on dual-energy CT for neuro-oncological patients. Br J Radiol 2023; 96:20230110. [PMID: 37493227 PMCID: PMC10461272 DOI: 10.1259/bjr.20230110] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2023] [Revised: 06/01/2023] [Accepted: 06/14/2023] [Indexed: 07/27/2023] Open
Abstract
OBJECTIVE Several studies have shown that dual-energy CT (DECT) can lead to improved accuracy for proton range estimation. This study investigated the clinical benefit of reduced range uncertainty, enabled by DECT, in robust optimisation for neuro-oncological patients. METHODS DECT scans for 27 neuro-oncological patients were included. Commercial software was applied to create stopping-power ratio (SPR) maps based on the DECT scan. Two plans were robustly optimised on the SPR map, keeping the beam and plan settings identical to the clinical plan. One plan was robustly optimised and evaluated with a range uncertainty of 3% (as used clinically; denoted 3%-plan); the second plan applied a range uncertainty of 2% (2%-plan). Both plans were clinical acceptable and optimal. The dose-volume histogram parameters were compared between the two plans. Two experienced neuro-radiation oncologists determined the relevant dose difference for each organ-at-risk (OAR). Moreover, the OAR toxicity levels were assessed. RESULTS For 24 patients, a dose reduction >0.5/1 Gy (relevant dose difference depending on the OAR) was seen in one or more OARs for the 2%-plan; e.g. for brainstem D0.03cc in 10 patients, and hippocampus D40% in 6 patients. Furthermore, 12 patients had a reduction in toxicity level for one or two OARs, showing a clear benefit for the patient. CONCLUSION Robust optimisation with reduced range uncertainty allows for reduction of OAR toxicity, providing a rationale for clinical implementation. Based on these results, we have clinically introduced DECT-based proton treatment planning for neuro-oncological patients, accompanied with a reduced range uncertainty of 2%. ADVANCES IN KNOWLEDGE This study shows the clinical benefit of range uncertainty reduction from 3% to 2% in robustly optimised proton plans. A dose reduction to one or more OARs was seen for 89% of the patients, and 44% of the patients had an expected toxicity level decrease.
Collapse
Affiliation(s)
- Vicki Trier Taasti
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Esther Decabooter
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Daniëlle Eekers
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Inge Compter
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Ilaria Rinaldi
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Marta Bogowicz
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Tim van der Maas
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Esther Kneepkens
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Jacqueline Schiffelers
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Cissy Stultiens
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Nicole Hendrix
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Mirthe Pijls
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Rik Emmah
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Gabriel Paiva Fonseca
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Mirko Unipan
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| | - Wouter van Elmpt
- Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
| |
Collapse
|
2
|
Hinault P, Gardin I, Gouel P, Decazes P, Thureau S, Veresezan O, Souchay H, Vera P, Gensanne D. Characterization of positioning uncertainties in PET-CT-MR trimodality solutions for radiotherapy. J Appl Clin Med Phys 2022; 23:e13617. [PMID: 35481611 PMCID: PMC9278679 DOI: 10.1002/acm2.13617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 01/26/2022] [Accepted: 03/28/2022] [Indexed: 11/13/2022] Open
Abstract
The purpose of this study was to evaluate the positioning uncertainties of two PET/CT‐MR imaging setups, C1 and C2. Because the PET/CT data were acquired on the same hybrid device with automatic image registration, experiments were conducted using CT‐MRI data. In C1, a transfer table was used, which allowed the patient to move from one imager to another while maintaining the same position. In C2, the patient stood up and was positioned in the same radiotherapy treatment position on each imager. The two setups provided a set of PET/CT and MR images. The accuracy of the registration software was evaluated on the CT‐MRI data of one patient using known translations and rotations of MRI data. The uncertainties on the two setups were estimated using a phantom and a cohort of 30 patients. The accuracy of the positioning uncertainties was evaluated using descriptive statistics and a t‐test to determine whether the mean shift significantly deviated from zero (p < 0.05) for each setup. The maximum registration errors were less than 0.97 mm and 0.6° for CT‐MRI registration. On the phantom, the mean total uncertainties were less than 2.74 mm and 1.68° for C1 and 1.53 mm and 0.33° for C2. For C1, the t‐test showed that the displacements along the z‐axis did not significantly deviate from zero (p = 0.093). For C2, significant deviations from zero were present for anterior‐posterior and superior‐inferior displacements. The mean total uncertainties were less than 4 mm and 0.42° for C1 and less than 1.39 mm and 0.27° for C2 in the patients. Furthermore, the t‐test showed significant deviations from zero for C1 on the anterior‐posterior and roll sides. For C2, there was a significant deviation from zero for the left‐right displacements.This study shows that transfer tables require careful evaluation before use in radiotherapy.
Collapse
Affiliation(s)
- Pauline Hinault
- QuantIF-LITIS EA4108, University of Rouen Normandie, Rouen, France.,GE Healthcare, Buc, France
| | - Isabelle Gardin
- QuantIF-LITIS EA4108, University of Rouen Normandie, Rouen, France.,Nuclear Medicine Department, Henri Becquerel Cancer Center, Rouen, France
| | - Pierrick Gouel
- QuantIF-LITIS EA4108, University of Rouen Normandie, Rouen, France.,Nuclear Medicine Department, Henri Becquerel Cancer Center, Rouen, France
| | - Pierre Decazes
- QuantIF-LITIS EA4108, University of Rouen Normandie, Rouen, France.,Nuclear Medicine Department, Henri Becquerel Cancer Center, Rouen, France
| | - Sebastien Thureau
- QuantIF-LITIS EA4108, University of Rouen Normandie, Rouen, France.,Radiotherapy Department, Henri Becquerel Cancer Center, Rouen, France
| | - Ovidiu Veresezan
- Radiotherapy Department, Henri Becquerel Cancer Center, Rouen, France
| | | | - Pierre Vera
- QuantIF-LITIS EA4108, University of Rouen Normandie, Rouen, France.,Nuclear Medicine Department, Henri Becquerel Cancer Center, Rouen, France
| | - David Gensanne
- QuantIF-LITIS EA4108, University of Rouen Normandie, Rouen, France.,Radiotherapy Department, Henri Becquerel Cancer Center, Rouen, France
| |
Collapse
|
3
|
Koike Y, Ohira S, Teraoka Y, Matsumi A, Imai Y, Akino Y, Miyazaki M, Nakamura S, Konishi K, Tanigawa N, Ogawa K. Pseudo low-energy monochromatic imaging of head and neck cancers: Deep learning image reconstruction with dual-energy CT. Int J Comput Assist Radiol Surg 2022; 17:1271-1279. [PMID: 35415780 DOI: 10.1007/s11548-022-02627-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Accepted: 03/24/2022] [Indexed: 11/29/2022]
Abstract
PURPOSE Low-energy virtual monochromatic images (VMIs) derived from dual-energy computed tomography (DECT) systems improve lesion conspicuity of head and neck cancer over single-energy CT (SECT). However, DECT systems are installed in a limited number of facilities; thus, only a few facilities benefit from VMIs. In this work, we present a deep learning (DL) architecture suitable for generating pseudo low-energy VMIs of head and neck cancers for facilities that employ SECT imaging. METHODS We retrospectively analyzed 115 patients with head and neck cancers who underwent contrast enhanced DECT. VMIs at 70 and 50 keV were used as the input and ground truth (GT), respectively. We divided them into two datasets: for DL (104 patients) and for inference with SECT (11 patients). We compared four DL architectures: U-Net, DenseNet-based, and two ResNet-based models. Pseudo VMIs at 50 keV (pVMI50keV) were compared with the GT in terms of the mean absolute error (MAE) of Hounsfield unit (HU) values, peak signal-to-noise ratio (PSNR), and structural similarity (SSIM). The HU values for tumors, vessels, parotid glands, muscle, fat, and bone were evaluated. pVMI50keV were generated from actual SECT images and the HU values were evaluated. RESULTS U-Net produced the lowest MAE (13.32 ± 2.20 HU) and highest PSNR (47.03 ± 2.33 dB) and SSIM (0.9965 ± 0.0009), with statistically significant differences (P < 0.001). The HU evaluation showed good agreement between the GT and U-Net. U-Net produced the smallest absolute HU difference for the tumor, at < 5.0 HU. CONCLUSION Quantitative comparisons of physical parameters demonstrated that the proposed U-Net could generate high accuracy pVMI50keV in a shorter time compared with the established DL architectures. Although further evaluation on diagnostic accuracy is required, our method can help obtain low-energy VMI from SECT images without DECT systems.
Collapse
Affiliation(s)
- Yuhei Koike
- Department of Radiology, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-1010, Japan.
| | - Shingo Ohira
- Department of Radiation Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 537-8567, Japan
| | - Yuri Teraoka
- GE Healthcare Japan Corporation, 4-7-127 Asahigaoka, Hino, Tokyo, 191-8503, Japan
| | - Ayako Matsumi
- GE Healthcare Japan Corporation, 4-7-127 Asahigaoka, Hino, Tokyo, 191-8503, Japan
| | - Yasuhiro Imai
- GE Healthcare Japan Corporation, 4-7-127 Asahigaoka, Hino, Tokyo, 191-8503, Japan
| | - Yuichi Akino
- Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Masayoshi Miyazaki
- Department of Radiation Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 537-8567, Japan
| | - Satoaki Nakamura
- Department of Radiology, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-1010, Japan
| | - Koji Konishi
- Department of Radiation Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 537-8567, Japan
| | - Noboru Tanigawa
- Department of Radiology, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-1010, Japan
| | - Kazuhiko Ogawa
- Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| |
Collapse
|
4
|
Beddok A, Calugaru V, de Marzi L, Graff P, Dumas JL, Goudjil F, Dendale R, Minsat M, Verrelle P, Buvat I, Créhange G. Clinical and technical challenges of cancer reirradiation: Words of wisdom. Crit Rev Oncol Hematol 2022; 174:103655. [PMID: 35398521 DOI: 10.1016/j.critrevonc.2022.103655] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Revised: 03/13/2022] [Accepted: 03/15/2022] [Indexed: 12/25/2022] Open
Abstract
Since the development of new radiotherapy techniques that have improved healthy tissue sparing, reirradiation (reRT) has become possible. The selection of patients eligible for reRT is complex given that it can induce severe or even fatal side effects. The first step should therefore be to assess, in the context of multidisciplinary staff meeting, the patient's physical status, the presence of sequelae resulting from the first irradiation and the best treatment option available. ReRT can be performed either curatively or palliatively to treat a cancer-related symptom that is detrimental to the patient's quality of life. The selected techniques for reRT should provide the best protection of healthy tissue. The construction of target volumes and the evaluation of constraints regarding the doses that can be used in this context have not yet been fully codified. These points raised in the literature suggest that randomized studies should be undertaken to answer pending questions.
Collapse
Affiliation(s)
- Arnaud Beddok
- Department of Radiation Oncology. Institut Curie, PSL Research University, Paris - Saint Cloud-Orsay. France; Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), U1288 Université Paris Saclay/Inserm/Institut Curie. Orsay. France; Proton Therapy Center. Institut Curie, PSL Research University, Orsay. France.
| | - Valentin Calugaru
- Department of Radiation Oncology. Institut Curie, PSL Research University, Paris - Saint Cloud-Orsay. France; Proton Therapy Center. Institut Curie, PSL Research University, Orsay. France
| | - Ludovic de Marzi
- Department of Radiation Oncology. Institut Curie, PSL Research University, Paris - Saint Cloud-Orsay. France; Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), U1288 Université Paris Saclay/Inserm/Institut Curie. Orsay. France; Proton Therapy Center. Institut Curie, PSL Research University, Orsay. France
| | - Pierre Graff
- Department of Radiation Oncology. Institut Curie, PSL Research University, Paris - Saint Cloud-Orsay. France
| | - Jean-Luc Dumas
- Department of Radiation Oncology. Institut Curie, PSL Research University, Paris - Saint Cloud-Orsay. France
| | - Farid Goudjil
- Department of Radiation Oncology. Institut Curie, PSL Research University, Paris - Saint Cloud-Orsay. France; Proton Therapy Center. Institut Curie, PSL Research University, Orsay. France
| | - Rémi Dendale
- Department of Radiation Oncology. Institut Curie, PSL Research University, Paris - Saint Cloud-Orsay. France; Proton Therapy Center. Institut Curie, PSL Research University, Orsay. France
| | - Mathieu Minsat
- Department of Radiation Oncology. Institut Curie, PSL Research University, Paris - Saint Cloud-Orsay. France
| | - Pierre Verrelle
- Department of Radiation Oncology. Institut Curie, PSL Research University, Paris - Saint Cloud-Orsay. France
| | - Irène Buvat
- Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), U1288 Université Paris Saclay/Inserm/Institut Curie. Orsay. France
| | - Gilles Créhange
- Department of Radiation Oncology. Institut Curie, PSL Research University, Paris - Saint Cloud-Orsay. France; Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), U1288 Université Paris Saclay/Inserm/Institut Curie. Orsay. France; Proton Therapy Center. Institut Curie, PSL Research University, Orsay. France
| |
Collapse
|
5
|
Cardenas CE, Blinde SE, Mohamed ASR, Ng SP, Raaijmakers C, Philippens M, Kotte A, Al-Mamgani AA, Karam I, Thomson DJ, Robbins J, Newbold K, Fuller CD, Terhaard C, On Behalf Of The, Bahig H, Blanchard P, Dehnad H, Doornaert P, Elhalawani H, Frank SJ, Garden A, Gunn GB, Hamming-Vrieze O, Kamal M, Kasperts N, Lee LW, McDonald BA, McPartlin A, Meheissen MA, Morrison WH, Navran A, Nutting CM, Pameijer F, Phan J, Poon I, Rosenthal DI, Smid EJ, Sykes AJ. Comprehensive Quantitative Evaluation of Variability in MR-guided Delineation of Oropharyngeal Gross Tumor Volumes and High-risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study. Int J Radiat Oncol Biol Phys 2022; 113:426-436. [PMID: 35124134 DOI: 10.1016/j.ijrobp.2022.01.050] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Revised: 01/12/2022] [Accepted: 01/26/2022] [Indexed: 02/02/2023]
Abstract
PURPOSE Tumor and target volume manual delineation remains a challenging task in head-and-neck cancer radiotherapy. The purpose of this study was to conduct a multi-institutional evaluation of manual delineations of gross tumor volume (GTV), high-risk clinical target volume (CTV), parotids, and submandibular glands on treatment simulation MR scans of oropharyngeal cancer (OPC) patients. METHODS Pre-treatment T1-weighted (T1w), T1-weighted with gadolinium contrast (T1w+C) and T2-weighted (T2w) MRI scans were retrospectively collected for 4 OPC patients under an IRB-approved protocol. The scans were provided to twenty-six radiation oncologists from seven international cancer centers who participated in this delineation study. In addition, patients' clinical history and physical examination findings, along with a medical photographic image and radiological results, were provided. The contours were compared using overlap/distance metrics using both STAPLE and pair-wise comparisons. Lastly, participants completed a brief questionnaire to assess participants' experience and CTV delineation institutional practices. RESULTS Large variability was measured between observers' delineations for GTVs and CTVs. The mean Dice Similarity Coefficient values across all physicians' delineations for GTVp, GTVn, CTVp, and CTVn were 0.77, 0.67, 0.77, and 0.69, respectively, for STAPLE comparison and 0.67, 0.60, 0.67, and 0.58, respectively, for pair-wise analysis. Normal tissue contours were defined more consistently when considering overlap/distance metrics. The median radiation oncology clinical experience was 7 years. The median experience delineating on MRI was 3.5 years. The GTV-to-CTV margin used was 10 mm for six of seven participant institutions. One institution used 8 mm and three participants (from three different institutions) used a margin of 5 mm. CONCLUSION The data from this study suggests that appropriate guidelines, contouring quality assurance sessions, and training are still needed for the adoption of MR-based treatment planning for head-and-neck cancers. Such efforts should play a critical role in reducing delineation variation and ensure standardization of target design across clinical practices.
Collapse
Affiliation(s)
- Carlos E Cardenas
- Department of Radiation Oncology, The University of Alabama at Birmingham, Birmingham, AL, USA.
| | - Sanne E Blinde
- Department of Radiation Oncology, Klinikum Kassel, Kassel, Germany
| | - Abdallah S R Mohamed
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Sweet Ping Ng
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Olivia Newton-John Cancer Centre, Austin Health, Melbourne, Australia
| | - Cornelis Raaijmakers
- Department of Radiotherapy, Division of Imaging & Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Marielle Philippens
- Department of Radiotherapy, Division of Imaging & Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Alexis Kotte
- Department of Radiotherapy, Division of Imaging & Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Abrahim A Al-Mamgani
- Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Irene Karam
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Science Centre, University of Toronto, Toronto, ON, Canada
| | - David J Thomson
- Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK
| | - Jared Robbins
- Department of Radiation Oncology, University of Arizona, Tucson, Arizona, USA
| | - Kate Newbold
- Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
| | - Clifton D Fuller
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
| | - Chris Terhaard
- Department of Radiotherapy, Division of Imaging & Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
| | - On Behalf Of The
- Department of Radiation Oncology, The University of Alabama at Birmingham, Birmingham, AL, USA
| | - Houda Bahig
- Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
| | - Pierre Blanchard
- Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
| | - Homan Dehnad
- Department of Radiotherapy, Division of Imaging & Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Patricia Doornaert
- Department of Radiotherapy, Division of Imaging & Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Hesham Elhalawani
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Steven J Frank
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Adam Garden
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - G Brandon Gunn
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Olga Hamming-Vrieze
- Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Mona Kamal
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Nicolien Kasperts
- Department of Radiotherapy, Division of Imaging & Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Lip Wai Lee
- Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK
| | - Brigid A McDonald
- Department of Radiation Oncology, The University of Alabama at Birmingham, Birmingham, AL, USA
| | - Andrew McPartlin
- Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK
| | - Mohamed Am Meheissen
- Alexandria Clinical Oncology Department, Alexandria University, Alexandria, Egypt
| | - William H Morrison
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Arash Navran
- Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | | | - Frank Pameijer
- Department of Radiology, Division of Imaging & Oncology, University Medical Center, Utrecht, The Netherlands
| | - Jack Phan
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Ian Poon
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Science Centre, University of Toronto, Toronto, ON, Canada
| | - David I Rosenthal
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Ernst J Smid
- Department of Radiotherapy, Division of Imaging & Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Andrew J Sykes
- Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK
| |
Collapse
|
6
|
O'Connor LM, Skehan K, Choi JH, Simpson J, Martin J, Warren-Forward H, Dowling J, Greer P. Optimisation and validation of an integrated magnetic resonance imaging-only radiotherapy planning solution. Phys Imaging Radiat Oncol 2021; 20:34-39. [PMID: 34901474 PMCID: PMC8640865 DOI: 10.1016/j.phro.2021.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 10/05/2021] [Accepted: 10/10/2021] [Indexed: 11/19/2022] Open
Abstract
Background and purpose Magnetic resonance imaging (MRI)-only treatment planning is gaining in popularity in radiation oncology, with various methods available to generate a synthetic computed tomography (sCT) for this purpose. The aim of this study was to validate a sCT generation software for MRI-only radiotherapy planning of male and female pelvic cancers. The secondary aim of this study was to improve dose agreement by applying a derived relative electron and mass density (RED) curve to the sCT. Method and materials Computed tomography (CT) and MRI scans of forty patients with pelvic neoplasms were used in the study. Treatment plans were copied from the CT scan to the sCT scan for dose comparison. Dose difference at reference point, 3D gamma comparison and dose volume histogram analysis was used to validate the dose impact of the sCT. The RED values were optimised to improve dose agreement by using a linear plot. Results The average percentage dose difference at isocentre was 1.2% and the mean 3D gamma comparison with a criteria of 1%/1 mm was 84.0% ± 9.7%. The results indicate an inherent systematic difference in the dosimetry of the sCT plans, deriving from the tissue densities. With the adapted REDmod table, the average percentage dose difference was reduced to −0.1% and the mean 3D gamma analysis improved to 92.9% ± 5.7% at 1%/1 mm. Conclusions CT generation software is a viable solution for MRI-only radiotherapy planning. The option makes it relatively easy for departments to implement a MRI-only planning workflow for cancers of male and female pelvic anatomy.
Collapse
Affiliation(s)
- Laura M. O'Connor
- Department of Radiation Oncology, Calvary Mater Hospital, Newcastle, NSW, Australia
- School of Health Sciences, University of Newcastle, Newcastle, NSW, Australia
- Corresponding author at: Department of Radiation Oncology, Calvary Mater Hospital, Cnr Edith & Platt St, Waratah, Newcastle, NSW 2298, Australia.
| | - Kate Skehan
- Department of Radiation Oncology, Calvary Mater Hospital, Newcastle, NSW, Australia
| | - Jae H. Choi
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - John Simpson
- Department of Radiation Oncology, Calvary Mater Hospital, Newcastle, NSW, Australia
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - Jarad Martin
- Department of Radiation Oncology, Calvary Mater Hospital, Newcastle, NSW, Australia
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | | | - Jason Dowling
- School of Mathematical and Physical Sciences, University of Newcastle, Newcastle, NSW, Australia
- Australian E-Health Research Centre, Commonwealth Scientific and Industrial Research Organisation (CSIRO), Herston, QLD, Australia
| | - Peter Greer
- Department of Radiation Oncology, Calvary Mater Hospital, Newcastle, NSW, Australia
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| |
Collapse
|
7
|
Wang J, Wen J, Yan H. Recent Applications of Carbon Nanomaterials for microRNA Electrochemical Sensing. Chem Asian J 2020; 16:114-128. [DOI: 10.1002/asia.202001260] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Indexed: 12/24/2022]
Affiliation(s)
- Jiameng Wang
- College of Pharmaceutical Science Hebei University Institute of Life Science and Green Development, Key Laboratory of Pharmaceutical Quality Control of Hebei Province Baoding 071002 P. R. China
| | - Jia Wen
- College of Pharmaceutical Science Hebei University Institute of Life Science and Green Development, Key Laboratory of Pharmaceutical Quality Control of Hebei Province Baoding 071002 P. R. China
| | - Hongyuan Yan
- College of Pharmaceutical Science Hebei University Institute of Life Science and Green Development, Key Laboratory of Pharmaceutical Quality Control of Hebei Province Baoding 071002 P. R. China
- College of Public Health Hebei University Key Laboratory of Medicinal Chemistry and Molecular Diagnosis, Ministry of Education Baoding 071002 P. R. China
| |
Collapse
|